Back to results
US 2021/0275666 A1Published application
Combination therapy comprising axl/mer and pd-1/pd-l1 inhibitors
AssigneeIncyte Corporation
InventorsJonathan Rios-Doria, Holly K. Koblish
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to methods of treating cancer by administering a compound, which is an AXL/MER kinase inhibitor, in combination with an antibody, or an antibody fragment thereof, that binds to PD-1.
Claims21
A method of treating cancer in a patient, comprising administering to said patient:
- (i) Compound 1, having the structure:
- or a pharmaceutically acceptable salt thereof;
- and
- (ii) an antibody, or an antigen-binding fragment thereof, that binds to human PD-1, wherein the antibody comprises (ii-1) a variable heavy (VH) domain comprising VH complementarity determining region (CDR)1, VH CDR2, and VH CDR3;
- and (ii-2) a variable light (VL) domain comprising VL CDR1, VL CDR2, and VL CDR3;
- wherein:
- (a) the VH CDR1 comprises the amino acid sequence SYWMN (SEQ ID NO:6);
- (b) the VH CDR2 comprises the amino acid sequence VIHPSDSETWLDQKFKD (SEQ ID NO:7);
- (c) the VH CDR3 comprises the amino acid sequence EHYGTSPFAY (SEQ ID NO:8);
- (d) the VL CDR1 comprises the amino acid sequence RASESVDNYGMSFMNW (SEQ ID NO:9);
- (e) the VL CDR2 comprises the amino acid sequence AASNQGS (SEQ ID NO:10);
- and
- (f) the VL CDR3 comprises the amino acid sequence QQSKEVPYT (SEQ ID NO:11).
10 more elements
Dependencies are inferred from the claim text.